Pancreatic Cancer Research

ResearcherChinese University of Hong KongActive in the last 2 years

Zhi‐Xiu Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2840-6179; OpenAlex author ID A5004560402. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters. Co-author DOI 10.1016/j.jare.2024.09.006↗
  2. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Last author DOI 10.1186/s13046-022-02270-z↗
  3. Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies. Last author DOI 10.18632/oncotarget.17761↗
  4. Brucein D, a Naturally Occurring Tetracyclic Triterpene Quassinoid, Induces Apoptosis in Pancreatic Cancer through ROS-Associated PI3K/Akt Signaling Pathway. Last author DOI 10.3389/fphar.2017.00936↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan‐Fang Xian · 3 shared papers, 2017–2025 · strength 0.51
  2. Hong‐Xi Xu · 2 shared papers, 2022–2025 · strength 0.44
  3. Juan Zhang · 2 shared papers, 2022–2025 · strength 0.44
  4. William Chi Shing Cho · 2 shared papers, 2022–2025 · strength 0.44
  5. Yulin Wu · 1 shared paper, 2025 · strength 0.28
  6. Yang Li · 1 shared paper, 2022 · strength 0.16
  7. Zheng Lu · 2 shared papers, 2017 · strength 0.15
  8. Zhengquan Lai · 2 shared papers, 2017 · strength 0.15
  9. Po Sing Leung · 2 shared papers, 2017 · strength 0.15
  10. Zhao‐Shen Li · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.